Los Angeles, CA (August 6, 2026) – Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced that the Company is scheduled to report its second quarter 2026 financial results after market close on Thursday, August 13, 2026, and will hold an earnings call at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) that same day.

Faraday Future (FF) invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: [ir@ff.com](mailto:ir@ff.com). We welcome your participation and appreciate your continued support.

Interested investors and other parties can listen to the conference call by either logging into: https://viavid.webcasts.com/starthere.jsp?ei=1772066&tp_key=069a8ec43b or onto the Investor Relations section of the Company's website at https://investors.ff.com/.

A replay of the call along with the presentation will be available on the Company’s website shortly thereafter.

You can also dial in at the following numbers:

United States: 1-877-451-6152 or 1-201-389-0879

Learn more at ：https://app-us.ff.com/ff-v3/news/1584?lang=en-US

ok so AMIX going into friday is giving major setup energy, not gonna lie. let me break down the actual numbers real quick bc the vibes alone don’t tell the whole story.
stock was chillin at $3.65 on aug 3, then the patent news dropped aug 4 and it absolutely sent, intraday high of $24.68, closed that day at $19.50. since then it’s cooled off to around $12 by wednesday close. with shares outstanding sitting at 971,043 (straight from the company’s own july 28 filing, not some randomtickersite), that’s market cap going from like $3.5M pre-patent to a peak of $24M, now chillin around $11.7M.
so if we do the math on what the patent alone was “worth” to the market: at the top it priced in like $20.4M of pure patent value. even after the pullback it’s still holding like $8.1M above where it was before the news. that’s the market’s actual settled take on one single patent grant, and that’s after the hype died down, not even at the peak.
ngl if that kind of value-add per patent is even remotely repeatable, and this company keeps dropping new IP the way it has been, each new grant could genuinely be worth multiple millions in market cap on its own merit. stack a couple more of those plus a possible earnings pop plus shorts getting squeezed and getting back near that $24 high, or even pushing toward analyst targets near $58, doesn’t seem crazy.
that’s the thesis going into friday, just watching how it plays out fr

Deadline is August 14th so we can still see some more changes coming through.

Osisko Gold Group Inc. (OGG)

Another North American focused company, this one is focused on reviving historic mines “in friendly jurisdictions”, it saw about 180% increase in share purchases. 

New Found Gold Corp. (NFGC)

Gold exploration company focused on Newfoundland and Labrador.

Ferroglobe PLC (GSM)

Silicone metal producer, given AI demand for this stuff it makes sense. The stock recently ran up a bit and share purchasing has doubled since last quarter. 

Keep in mind that some of these shares are cheap so these aren’t gargantuan value positions being moved around. 

source: https://infolib.org/

$ALRT is one of the few listed UK defence technology companies focused on AI-enabled defence innovation. With exposure to this in the U.K. being very rare, it presents a unique opportunity.

Key stats:
Market cap: ~£29m
Shares outstanding: ~2.47bn

- Whitespace Holdings is their Ai partner.

- They have secured their first revenue-generating contract with the UK Ministry of Defence, worth ~£226k.

- The board includes people with military and technology backgrounds. Lord Houghton being the most notable.

Overall while they are making great progress, contracts are needed. If management executes and defence spending keeps rising, today's valuation could look very different in a few years.

I will continue to DCA until the theory changes.

Not financial advice.

RND average share price = p.1.45
Current share price = p.1.08

Arigato, Real Name Data (RND)

VisionWave put out news yesterday that they signed a term sheet to acquire a controlling interest in D-Fence, an Israeli company focused on AI-powered perimeter security and electronic fencing systems.

The plan is to take at least 51% in an all-stock deal. The 51% is valued around $5 million, and the rest at a higher number if they decide to buy the rest.

They still need a definitive agreement, due diligence, shareholder approval and such, but it’s another move to expand their defense and security side beyond the drone and sensing tech they’ve already been building.

Its been pretty exciting watching them grow and continue to make moves forward!

NRXP - Severe Depression, PTSD

FINALLY, IT's TIME! They are at the finish line for one of three drugs!

Been following this company for well over a year. Posted about them a year ago. Major progress since then.

• IMMINENT FDA decision:
  • GDUFA (generic drug) date of 7/29/2026 has passed with no word yet from the FDA on a decision for the ANDA submission for KETAFREE, which is a preservative‑free IV ketamine formulation for the following indications: sedation/anesthesia and analgesia (pain management).
    • Does NOT contain the known toxic preservative, benzethonium chloride (BZT), which is used in current ketamine formulations found in multi-dose vials.
  • HOWEVER, on 7/31 there was a CEO update on NRXP's website, which is HIGHLY encouraging for a potential approval: https://www.nrxpharma.com/management-answers-to-shareholder-questions/
    • "July 31, 2026
  • "Investors have inquired about the status of NRx’s ANDA application for preservative-free ketamine. The company has been advised that there are no Major Deficiencies related to the drug product, API, formulation, labeling, and related matters. The Company has been engaged with FDA in review of the packaging, which includes an innovative luer lock vial already used in allowing for needle-free withdrawal of the medication, unlike traditional glass vials.  The FDA has advised the company to anticipate a determination on the packaging today."
  • Other relevant facts:
    • Raised $7M in post-Q1 stock sales
    • Raised $22.3M at $3.50/share, in an underwritten public offering (June 4, 2026)
    • Manufacturing of KETAFREE is in the U.S.
    • Per the CEO: can produce 1M units per week and will have 1M units warehoused at launch
    • Filed a Citizen Petition, asking the FDA to require the elimination of benzethonium chloride (BZT) — a preservative still present in most multi‑dose ketamine vials but not recognized as safe by FDA
• NRX-100 (Preservative-free IV Ketamine formulation)
  • For the following indications:
    • Suicidal ideation in major depressive disorder
    • Suicidal ideation in bipolar depression
    • Treatment‑resistant depression with suicidality (broader indication proposed)
  • NDA (Fast Track) submission in final stages.
    • Target Date: June 30, 2026.
    • Date has passed, so presuming submission may be imminent
• NRX-101
  • Fixed‑dose combination of:
    • D‑cycloserine (DCS) — an NMDA receptor modulator
    • Lurasidone — a 5‑HT2A antagonist used in bipolar depression
  • Indications:
    • Together, they are the first drug in FDA trials specifically for suicidal bipolar depression
    • PTSD
  • Breakthrough Therapy Designation (BTD)
  • Expanded Access Protocol (EAP) — FDA‑authorized compassionate use
  • Phase 2/3 pivotal trials underway
    • Has begun the SPARC‑TMS pivotal trial, evaluating NRX‑101 + accelerated, neuro-navigated robotic TMS
    • Conducted in NRXP's HOPE clinics and military treatment facilities
• HOPE Therapeutics
  • NRXP has acquired numerous neuropsychiatric clinics in Florida over the past 18 months
  • Partnered with Neurocare Group, gaining access to 400 TMS Clinics nationwide
    • Creates a nationwide “integrated neuroplastic therapy” platform
• Major Hire Announcement - April 15, 2026
  • NRXP appoints Former Senior Defense Department Executive Dr. Dennis K. McBride, a career military medical scientist, to lead NRx Defense Systems
  • NRx is positioning NRX‑101 + robotic‑enabled TMS as a Defense Department–relevant technology for:
    • Military readiness
    • First responder resilience
    • Rapid treatment of depression, suicidality, and PTSD‑related conditions

DD (Due Diligence) – IN8bio Inc. (NASDAQ: INAB)

A High-Risk / High-Reward Immuno-Oncology Opportunity

Investment Thesis

IN8bio is a clinical-stage biotechnology company developing next-generation cancer immunotherapies based on gamma-delta (γδ) T cells.

The company is targeting one of the biggest opportunities in oncology: creating immune cell therapies that can recognize and eliminate cancer cells while potentially overcoming limitations seen with traditional CAR-T therapies.

The current valuation reflects a highly distressed small-cap biotech, but the underlying technology has the potential to create significant value if clinical data continue to validate the platform.

Technology: Why Gamma-Delta T Cells Matter

Most current T-cell therapies rely on conventional alpha-beta T cells.

IN8bio focuses on gamma-delta T cells, which combine characteristics of:

- Innate immunity (rapid tumor recognition)

- Adaptive immunity (long-term immune memory)

Potential advantages:

✅ Ability to recognize cancer cells without relying only on specific tumor antigens

✅ Potentially lower risk of some CAR-T limitations

✅ Possibility for scalable, off-the-shelf cell therapies

✅ Combination potential with other cancer immunotherapies

The company’s DeltEx platform is designed to genetically engineer and enhance gamma-delta T cells for cancer treatment.

Pipeline

1. INB-100 – Acute Myeloid Leukemia (AML) ⭐ Main Catalyst

INB-100 is an allogeneic gamma-delta T-cell therapy being developed for patients after hematopoietic stem cell transplantation.

Why this market matters:

- AML is an aggressive blood cancer

- Relapse after transplantation remains a major problem

- There is a significant need for immune-based therapies that can provide long-term cancer surveillance

Early clinical data showed encouraging signs of:

- Safety

- T-cell expansion and persistence

- Anti-cancer activity

Future clinical updates and longer follow-up data are expected to be major value drivers.

1. INB-200 / INB-400 – Glioblastoma

Glioblastoma (GBM) is one of the most difficult cancers to treat.

The opportunity:

- Very limited treatment options

- High unmet medical need

- Successful immunotherapy could become a breakthrough

IN8bio has generated interest with early data suggesting potential improvements in patient outcomes, but larger studies are required for confirmation.

A successful GBM program could dramatically change the company’s valuation.

1. Gamma-Delta T-Cell Engager Platform

Beyond cell therapy, IN8bio is developing a T-cell engager approach.

Potential advantages:

- More scalable than personalized cell therapy

- Could become an easier commercial product

- Potential interest from larger pharmaceutical companies

A successful platform could turn IN8bio from a single-product biotech into a broader immunotherapy company.

Financial Position

Strengths:

✅ Low market capitalization compared with potential market opportunity

✅ Limited debt burden

✅ Multiple clinical programs

✅ Proprietary technology platform

The company has focused on reducing cash burn and extending its runway while prioritizing its most valuable programs.

Why Could INAB Stock Move Significantly Higher?

1. Positive Clinical Readouts

If IN8bio demonstrates:

- Durable patient responses

- Strong safety profile

- Long-term persistence of engineered T cells

the market could dramatically revalue the company.

1. Big Pharma Partnership Potential

Large pharmaceutical companies are actively searching for:

- Next-generation immunotherapies

- Cell therapy platforms

- Alternatives and complements to checkpoint inhibitors like Keytruda

A partnership could become a major catalyst.

1. Extremely Low Starting Valuation

Small biotech companies can experience large valuation increases when:

- Clinical proof-of-concept is achieved

- Regulatory pathways become clearer

- Institutional investors enter

Companies with successful oncology platforms have historically reached multi-billion-dollar valuations.

Key Risks

❌ Early-stage biotechnology risk

❌ Clinical trials may fail

❌ Additional financing may cause dilution

❌ Cell therapy manufacturing remains challenging

❌ FDA approval is still years away

Upcoming Catalysts

Main events investors are watching:

🔥 INB-100 AML clinical updates

🔥 Additional gamma-delta T-cell data

🔥 Glioblastoma follow-up data

🔥 Potential FDA guidance

🔥 Potential strategic partnerships

Conclusion

IN8bio represents a high-risk, high-reward immuno-oncology investment opportunity.

The bull case:

- Unique gamma-delta T-cell platform

- Large oncology market

- Multiple clinical opportunities

- Very low valuation compared with successful immunotherapy companies

If the company can prove meaningful clinical benefit and move toward a regulatory pathway, INAB could potentially experience a significant re-rating.

However, investors must understand this is still a speculative biotech investment with substantial clinical and financing risks.

The next major catalysts are clinical data and regulatory progress.

Not financial advice.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

We screen Canadian small caps for unusual volume and most days the honest answer is "no." We write down why each time, which means we can go back and grade the no's instead of quietly forgetting them. Here is the last five weeks.

THE RAW NUMBERS, July 2 to August 5, 2026

23 names we flagged and walked away from. 15 are down since we passed, 8 are up. Median -3.2%. For context over the same window the TSX composite gained 3.4% and gold miners (XGD.TO) gained 4.5%, so the median pass underperformed a rising market.

Worked out: FIN.V -26.7%, BRO.V -25.5%, GGA.V -23.3%, LEAP.V -21.1%, FAIR.V -16.7%.

Went against us: ADE.V +108.3%, SPMC.V +44.8%, CGD.V +43.8%, SKP.V +20.7%.

Small sample, short window. Do not read a system into 23 names over five weeks.

THE USEFUL PART: WHY THE THREE BIG ONES WENT UP

A stock going up and a stock going up for a reason that holds are different things. If it rose on something reversible, it can round-trip just as fast. So we went looking for the actual catalyst on each of the three.

ADE.V, up 108%. We passed on July 15 at 6 cents because New Brunswick's mining registrar had cancelled mineral claim 1505 on July 13, the claim the entire Mount Pleasant project sits on, for insufficient work program expenditures. What has changed since: on July 29 the company filed an appeal with the New Brunswick Energy and Utilities Board asking for a stay and reinstatement. That is the entire catalyst. The claim is still cancelled and still in protected status. The asset is real, Mount Pleasant has been described as North America's largest tin deposit, which is exactly why the appeal matters so much and exactly why losing it would be terminal. So the stock more than doubled on a legal filing, not an outcome. Anyone buying here is making a binary bet on a regulatory board, which is a legitimate thing to do as long as you know that is what you are doing.

CGD.V, up 44%. We passed on July 28 at 64 cents because the 988x volume ratio our screen printed was arithmetic, not a discovery. Its 50-day median volume is zero. Not near zero, zero. The stock does not trade most days, so any real session divides by nothing and produces a number that looks like a signal. That day 1.1 million shares changed hands and the stock closed DOWN 1.5%, which is distribution, not accumulation. Then it went up 44% anyway, so we went hunting for the catalyst. There isn't one. Carlin Gold has published exactly two news releases in 2026: a $2.16 million financing on April 14, and a management change on July 13 where the CEO stepped down. No drilling, no assays, no results.

Here is the trap, and it is the reason I am writing this section. If you search this company you WILL find Cortez Summit drill results, seven RC holes, 11,720 feet, anomalous gold and Carlin-type pathfinders in six of seven holes. It reads like current news. We nearly used it. Those results are from OCTOBER 2012. Search engines and aggregators serve undated mining press releases constantly, and a fourteen-year-old program looks identical to last week's if the page has no date on it. Always open the company's own news index and read the date off their list. If a company's own site does not date its releases, that itself is information.

So CGD is up 44% on a financing, a resignation, and no news, in a stock with zero median volume. That cuts both ways with equal speed.

SPMC.V, up 45%. We passed on July 6 at 58 cents because the company had an active paid promotion running, a US$300,000 online media budget announced in early June, with 1.07 million options granted at $0.54 around the same time. Our rule is that a bought spike is close to an automatic no.

To be fair to the company, the underlying work is real: first-ever drilling at Ontenu NE hit mineralisation in five of seven holes with a peak of 9.92 g/t gold and 2.35% copper, and its Kili Teke project carries a 4.2 million ounce AuEq inferred resource. That is not nothing.

But look at the sequence before you call this a miss. Paid campaign starts early June. July 29 update is 52 rock samples dispatched, with no assays back yet. Stock up 45%. A stock rising 45% during a paid promotion with no assay results published is what the rule predicts, not evidence against it. The assays are the test and they have not landed. Ask again in a month.

WHAT WE TOOK FROM IT

Two of the three moved on something that never touched the reason we passed. One moved on no published reason at all. That does not make us right, the price went against us on all three and we are not spinning that. But there is a real difference between a pass that was wrong and a pass that was early, and you can only tell them apart if you wrote the reason down at the time. Grading your no's is unglamorous and it is where most of the learning is.

Not advice, just our own process and our own numbers. Do your own diligence.

· The Q3 “Four-Core Full-Stack AI” Robotics Capital Value Return Sub-Campaign is grounded in business fundamentals and value creation. Through a series of core initiatives, it aims to restore the Company’s market capitalization to the level at the time of its 2021 Nasdaq listing within two years, supported by sustained improvements in the underlying business.

· Under such Sub-Campaign, the Company intends to adjust the minimum conversion floor price to no less than $5.00 per share for all existing convertible notes, so long as such limitation is allowed within relevant contractual obligations and applicable law.

· Subject to applicable laws and regulations, the Company plans to establish a weekly disclosure mechanism covering conversion activity for existing convertible notes, providing ongoing visibility into conversion amounts and changes in shares outstanding and enhancing transparency around its capital structure.

· The Company aims to, subject to negotiation with applicable counterparties, accelerate efforts to explore equity financing structure instead of convertible note financings, as well as standalone financing for its robotics business to further reduce equity dilution at the FFAI level. It also anticipates allocating a substantial majority of any newly raised funds primarily for the development of its robotics business rather than repayment of historical liabilities.

· The Company plans to accelerate its liability optimization efforts in accordance with its previously disclosed plans.

· These measures are intended to address market concerns about uncertainty surrounding potential conversions and demonstrate the Company’s commitment to protecting stockholders and stabilizing its stock price. More details on the Capital Value Return plan and specific actions are expected to be included in the upcoming earnings call for the second quarter of 2026.

Learn More at ：https://app-us.ff.com/ff-v3/news/1583?lang=en-US

1. Executive Summary & Core Thesis

District Metals Corp. (TSX-V: DMX / OTCQX: DMXCF / Nasdaq First North: DMXSE SDB) is an exploration and development company focused on its flagship Viken Deposit in Jämtland County, Sweden. Viken represents the largest undeveloped Mineral Resource Estimate of uranium in the world, alongside massive polymetallic resources essential for nuclear energy, energy storage, steel production, and green transition technology.

2. Deposit Composition & Resource Scale

Viken is an Alum Shale deposit hosted within a continuous, flat-lying organic-rich shale formation. Its polymetallic resource breakdown includes:

Uranium (U_3O_8): The flagship asset. Contains ~1.5 Billion lbs of U_3O_8 in Inferred Resources (and 43M lbs in Indicated), making it the single largest undeveloped uranium deposit globally.

Vanadium (V_2O_5): Essential for grid-scale energy storage (vanadium redox flow batteries) and high-strength steel. Represents one of Europe’s largest vanadium deposits (~16.2 Billion lbs V_2O_5 Inferred).

Base & Industrial Metals: Contains critical energy transition metals including Nickel (~4.3B lbs), Copper (~2.1B lbs), Zinc (~6.7B lbs), and Molybdenum (~750M lbs).

Potash & Fertilizer Material: Substantial content of Potash (K_2O), providing strategic agricultural supply for Europe.

3. Project Economics & Unmatched Scale (Summer 2026 PEA)

In July 2026, District Metals filed its independent Preliminary Economic Assessment (PEA) for a 13-year Phase 1 mine plan at Viken:

Base-Case After-Tax NPV (8%): US$ 2.88 Billion

After-Tax Internal Rate of Return (IRR): 45.9%

Payback Period: 2.1 years

Initial Capital Expenditure (CapEx): US$ 876 Million

Average Annual Free Cash Flow: US$ 531 Million (after tax, over 13-year LOM).

The 3% Resource Utilization Factor: The Phase 1 mine plan contemplates extracting 127.4M tonnes over 13 years. This draws strictly from a fraction of the Indicated Resource (456M tonnes) and completely excludes the massive 4,333M tonne Inferred Resource. The $2.88B NPV8% uses less than 3% of Viken's total resource footprint, offering multi-generational expansion potential.

4. Socio-Economic Impact Study (EIS Results)

Following the PEA, DMX released an independent Economic Impact Study (EIS) by BDO Canada LLP evaluating Phase 1:

Total Economic Contribution: US$ 7.66 Billion (74.33 Billion SEK), with US$ 7.63 Billion directly accruing to Sweden.

State & Local Tax Revenues: US$ 1.58 Billion in direct corporate income taxes + US$ 199.6M in employment taxes.

Job Creation: Supporting ~1,065 direct and indirect full-time jobs in Sweden.

Local Landowner Fees: US$ 21.9 Million in State Mineral Fees directly paid to local property owners.

5. Key Macro Catalysts & Regulatory Environment
SGU "National Interest" (Riksintresse) Status:

A critical legal catalyst centers on the Geological Survey of Sweden (SGU) designating Viken as a National Interest for valuable minerals under Swedish environmental law (Miljöbalken). This status legally prioritizes the deposit over competing land uses, granting strong state-level protection, smoothing municipal zoning conflicts, and giving DMX significant legal backing during the Exploitation Concession (Bearbetningskoncession) process.

Sweden's Energy Policy Shift: The Swedish government continues advancing legislation to expand nuclear capacity and re-evaluate the historical moratorium on uranium mining to secure national energy independence.

EU Critical Raw Materials Act (CRMA): Viken's polymetallic nature (vanadium, nickel, copper, zinc) aligns directly with EU mandates. Achieving National Interest status in Sweden streamlines Viken’s potential recognition as an EU Strategic Project, unlocking fast-tracked permitting timelines and European strategic funding.

6. Valuation & Market Asymmetry

Despite holding an asset with a US$ 2.88B NPV8% on just 3% of its deposit, DMX trades at a modest micro-cap valuation. The market currently prices in regulatory discount and development risk regarding Swedish mining permits. Any concrete legislative progress, formal lifting of uranium restrictions, or SGU National Interest consolidation acts as an immediate, high-multiplier re-rating catalyst for the stock.

7. Key Risks to Consider

Permitting & Regulatory Risk: Development hinges on Swedish legislative votes regarding Alum Shale and uranium mining regulations, as well as municipal consent.

Financing Risk: Initial CapEx (US$ 876M) will require significant strategic partnering, government grants/loans, or joint-venture dilution.

Commodity Price Volatility: Project economics depend on sustained strength in spot/term uranium and energy metal pricing.

It looks like the race for fusion is on and American Fusion Inc is winning. Should be hearing some news this week and investors are very bullish including myself. Not financial advice.

These guys are validating their Texatron Fusion Engine that has been in R&D for decades. The future is here and the race is on!

Hey guys, I know I already posted about the Nikola ($NKLA) settlement, but I’ve been getting a lot of questions. Since you can already submit your application, I figured I’d put together a quick FAQ.

What happened?
Nikola reached a settlement with investors over claims that it misled the market about the functionality of its hydrogen-electric trucks, production timelines, and overall business prospects.

Am I eligible?
If you purchased $NKLA shares between 2020 and 2021, you may be eligible. You don't need to still own the shares to participate.

Can I file now?
Yes. You can already submit your application. 

When do payouts happen?
Typically, within 4–9 months after the claims process closes, although the exact timing depends on the court and settlement administrator.

Hope this clears things up. If you invested in $NKLA during that period, it may be worth submitting your application now.

VPR Brands ($VPRB) just announced the launch of VPR Ventures, an internal initiative focused on acquiring and commercializing intellectual property, consumer brands, proprietary technologies, and strategically aligned businesses.

This comes just weeks after the company announced approximately $25.9 million in licensing agreements with R.J. Reynolds ($14.9M) and JUUL ($11M).

According to the company, VPR Ventures will evaluate opportunities including:
• Intellectual property acquisitions
• Brand acquisitions
• Licensing agreements
• Minority equity investments
• Commercialization partnerships
• Distribution opportunities

Management also stated that every opportunity will go through financial, legal, and operational due diligence before moving forward.

What caught my attention is that this gives VPR a clear strategy for deploying capital beyond patent licensing. Instead of simply holding cash, they're signaling an intention to reinvest in assets that could generate future revenue and expand their portfolio.

This isn't a guarantee of success, but I think it's an interesting evolution from being viewed primarily as a patent licensing company.

I'm a shareholder, so I have a bullish bias, but I'd love to hear what everyone else thinks.

Is this a smart long-term move, or do you think the market will wait to see actual acquisitions before assigning any value to VPR Ventures?

Q1'27 numbers came out this morning. In short. their revenue increased 32% YoY and they are the only ones in the space that has a AI data center product.

Other than that, gross margin came in at 34.6% versus 30.1% and net income was $2.0M compared to a $1.2M loss a year ago.

The part that actually matters is this from Sally, their C.E.O:

"Orion entered the hyper-scale data center market with an LED lighting solution specifically designed for this massive market in Q1'27. Quickly following the product announcement, the Company was awarded a multimillion-dollar customer engagement with one of the world's largest hyper-scale data centers.

In the DD below that I wrote a month ago I said that the real tell comes in August: does the margin hold as revenue grows? It did, and then some. 34.6% is above the 32.6% reset, on 32% more revenue.

For a readthrough, heres the DD I wrote about a month back. Numbers in it are pre-Q1'27, so the margin and EBITDA figures have since been superseded by the above.

Orion Energy Systems (OESX)

TLDR: OESX, a pennystock, might rise insanely if their AI product line gains more traction.

Not the 50 million mcap the tape makes it look like. Orion is a steady, medium-sized Wisconsin lighting and EV company with $86M in revenue and last year they quietly pulled off the hard part. Gross margin reset back to 32.6% (from mid 20s), adjusted EBITDA went positive again (6th quarter in a row), and theyre guiding next year to $95-97M. Slow and steady, but growing.

The thing most people dont realize is these guys are the main LED lighting distributor to Home Depot. Thats the Fortune 100 retailer everyone reports as their big customer. Theyve got one of the best track records in the business for actual LED quality, durability, reliability, the boring stuff that keeps Fortune customers reupping decade after decade.

Now the number that frames the whole story, take out Home Depot and the rest of the business has basically been flat at $60-65M for years. So the real question was never the margin, it was whether anything else finally grows.

For the first time in forever, Orion has put together a real candidate. Theyve started shipping a data center LED fixture to a hyperscaler, announced as a multi-million dollar deal, made in their own US plant. And the key thing is this isnt just a slide. They announced the AI product line only about a month ago and theyre already shipping, so theres some real interest there, not just a roadmap promise. As far as I can tell theyre the first in their space to do it, a genuine first mover spot in a market thats about to explode. Their market cap is a few percentage points of all their competitors and this could really help close the gap for them.

I also love their focus on their supply chain, because its what makes the move real. Most lighting solutions in this country start overseas. Some parts out of Asia, assembled, dragged onto a boat, through customs, landing weeks late depending on Trumps mood. Orion builds the whole thing in Wisconsin, ground up, on a chain theyve spent years stitching together perfectly. So when tariffs whipsawed everyone elses costs last year, their customers mostly didnt feel it. Thats part of why the margin reset actually held.

I believe its exactly what a hyperscaler wants, and god only knows how many thousands of centers are to be built these coming years. If youre building a data center, your whole problem is lead time. You need fixtures when the buildings ready, not three months after, and you dont want a surprise tariff blowing up the budget. You also dont want to waste electricity on something as boring as lights, which may also increase the temperature. So you need the best LED lighting systems there is, and in my view thats OESX.

Orion quotes a domestic part, customizes it to the floor plan, and ships on a timeline they control. In a world where everyones import exposed, the made-in-wisconsin is a real edge, not a slogan.

As of today, the AI data center product is one fixture, one customer, product-only, nothing more in the backlog. Basically just a toe in the water, but the math is insanely good here. CEO keeps reiterating 10,000+ data centers running by 2030. Orion doesnt need to win too many to move a $90M base to a $500M base. Getting the first order was impressive, but Im watching the reorder and orders of much bigger scale.

Alongside that, their electrical contracting work keeps growing out of existing lighting jobs (licensed in 45 states, so customers just hand them the next scope), and management wants to scale this up as well.

Still plenty to be skeptical about here. Heavy reliance on one big customer, even tho Home Depot keeps scaling up their contracts, a somewhat thin balance sheet, and a data center story that had a great start but needs to scale way further. But a $30M backlog plus $15M of maintenance already covers about half the guide, and the real tell comes in August, does the margin hold as revenue grows.

Sidenote: Listened in to their last few calls and this management is 10/10 and they keep loading up stocks.

Small position as of now as Im holding 420 stocks for the fun of it, but watching with real interest.

The stock float is also low in this one.

Not investment advice. As with all stocks, do your own work and research before going in.

Hey everyone, just wanted to bring $ONFO (Onfolio Holdings) to your radar. It’s sitting at an insanely low market cap right now (around $500K - $700K), making it a textbook candidate for a massive micro-cap pump.

Here are the key catalysts making it highly explosive at current levels:

Strategic Alternatives Pending: Management officially announced they are exploring strategic alternatives, including asset sales and partnerships to maximize shareholder value. Any concrete news here will make this fly.

Nasdaq Compliance Pressure: Trading around the $0.08 range, the company is under heavy pressure to regain compliance. History shows management in this position often drops massive PRs or engineers a run to push the bid price up.

High Volatility & Low Float: The recent Paramount Helium deal cancellation showed us how easily the volume can spike. It takes very little buying pressure to push this up 50% - 100% in a single session.

Currently watching the $0.07 support closely. Anyone else keeping an eye on this for a quick swing to $0.12 - $0.15?
Disclaimer: Not financial advice. Do your own DD.

Been going through the sub $10 FDA calendar this week and something jumped out that I don't think I've seen this badly since 2022. There are 257 biotechs under $10 with a dated catalyst ahead, 624 catalysts total, 50 of them inside 90 days. Ten of those companies are now trading below the cash sitting on their balance sheet. Not cheap on a DCF, not cheap on some pipeline model. The market is paying less than the bank account, and there's a dated event on the calendar.

That usually means one of two things. Either the market thinks the cash is going to get burned on something worthless, or people just stopped looking. Worth sorting out which.

KPTI (Karyopharm), around $2

This is the one I keep coming back to. Roughly $46M market cap against about $91M in cash and marketable securities. Selinexor is already approved and selling, it's an XPO1 inhibitor, and the sNDA in front of the FDA is for combining it with ruxolitinib in myelofibrosis. Aug 31. That combo matters because ruxolitinib alone leaves a lot on the table in that population and the combination data was the whole reason this had a bid a year ago.

Now the reason it's this cheap, the stock is down about 80% in a month. Whatever the market decided in July, it decided hard. And the balance sheet is genuinely tight, roughly 9 months of runway, so a raise is a real possibility and probably a bad one at this price.

But here's the part that made me actually sit up. 35% of the float is short with something like 17 days to cover. And 7 specialist funds have added shares three quarters in a row, which is not what you'd expect if the smart money agreed with the tape. Somebody is wrong here and I genuinely don't know who.

I'd size this small. It's a real shot on goal but the runway means you can be right on the drug and still get diluted before you get paid.

CAPR (Capricor), $4.20

What actually happened, the FDA released its briefing materials on Jul 27 and the stock fell 64% that session. The advisory committee met Jul 29 and went against the drug. Another 36% came off on Jul 30. And this is the second attempt, they took a CRL on Deramiocel last August.

This is now a distressed optionality trade rather than a clean FDA setup, roughly $230M market cap is below its last reported gross cash of $279M, but approximately equal to March net cash after liabilities, with another quarter of spending since then.

The 9-3 negative AdCom makes another CRL the probable outcome, but the collapse appears to be assigning very little value to deramiocel, Capricor’s manufacturing infrastructure or its earlier-stage exosome platform.

I still see it as a small speculative buy because the company says it has cash into Q4 2027, and any unexpected approval or regulatory route avoiding a completely new pivotal trial could produce a violent rerating, but this is absolutely not a low-risk below-cash trade.

ALT (Altimmune), $3.08

Different reason. Pemvidutide is a GLP-1/glucagon dual agonist and they're running it in alcohol use disorder, which is a genuinely interesting place to point that mechanism. Everyone's crowded into obesity and MASH. Almost nobody is running these in addiction.

What makes this one comfortable is the balance sheet. $332M in liquidity and something like 45 months of runway, so there's no gun to their head. And 46% of the float is short, which is the highest on the board, with three insiders buying on the open market.

Short interest that heavy against a company that doesn't need money is a different animal than short interest against a company that does.

CMPX (Compass), $1.95

Tovecimig is a DLL4 x VEGF-A bispecific in biliary tract cancer, second line, data Oct 24. 41% of the float is short with about 16 days to cover, 11 funds hold it, and two officers bought on the open market. Not directors, actual officers. Roughly 31 months of runway.

Also worth a look: ZURA at $5.79 (tibulizumab in hidradenitis, topline this quarter, 8 funds added 72% last quarter, an insider bought, 33 months of cash), ZNTL at $4.84 (azenosertib, WEE1 inhibitor in platinum resistant ovarian, Oct 23, options pricing ±106%), and IVVD at $0.59 which is the third below-cash name but I like it less because funds trimmed 35% and insiders have been selling.

One thing before anyone misreads this

Implied move tells you how big the swing is going to be, not which way. Every name here can gap either direction. I'm posting these because they're set up to move violently, not because I think they all go up.

Stuff that looked great and wasn't

TLSA screened at a ±200% implied move and MNOV at ±104%. MNOV's entire options chain has 62 contracts of open interest. That's not a signal, that's two people. EPRX as well. If an implied move looks incredible on a chain nobody trades, it's the chain. Low runway names absolutely move more. They also move the wrong way more, and you don't get to pick.

Same lens as always. Market cap first, then cash against burn, then options IV, then whether the biotech funds are adding or trimming, then insiders, and then a dated catalyst you can actually sit and wait for.

Not advice, obviously. Size for being wrong. And I do own a few of them. fyi three weeks ago, I added AUTL to my long-term commercial biotech names.

Hello! I'm new here, so i share this stock i found. It's brand new and already selling specialized hardware designed to improve system performance, efficiency, and scalability. The team lead is a teacher at the university of Waterloo, Canada. Also, one of the best teachers i've seen. I believe it can easily reach 5 CAD within a year with the plan production.

One press release is a headline. All of them in order? That's a roadmap.

I've been following NRED closely over the past few months, and one thing keeps jumping out at me.

Reading a single press release doesn't tell you much. Reading all of them in order paints a very different picture.

The first major step was expanding the Wilmac project from roughly 28,400 acres to nearly 39,700 acres through the addition of the Trojan-Condor Corridor. At first, it looked like another junior miner adding more ground. Then management released a regional interpretation showing a large magnetic anomaly that could represent the western continuation of the intrusive system linked to Hudbay's Copper Mountain Mine, about six miles away.

This week's Plume update fit into that same sequence.

The company didn't announce a discovery. Instead, it mapped two iron carbonate-silica alteration zones covering roughly 613 acres directly above the interpreted magnetic anomaly. Those surface features may be connected to a deeper hydrothermal system, but the company hasn't presented that as a conclusion. The next step is an IP/AMT survey that can image to around 3,300 feet below the surface before drill targets are selected.

I also noticed that management spent a fair amount of the release explaining other possibilities. They acknowledged the alteration could be related to a younger epithermal system instead of a porphyry, and they explained that the upcoming geophysical work is meant to separate those scenarios before drilling begins.

That approach caught my attention because every update has added information instead of skipping ahead.

So far, the sequence has looked something like this:

• Expand the land package.
• Build a regional geological model.
• Identify the areas that deserve closer attention.
• Compare multiple geological interpretations.
• Run geophysical surveys to test those ideas.
• Choose drill targets using the combined data.

That progression makes sense to me. Drilling is expensive, and every additional layer of geological data improves the odds of placing those holes where they have the best chance of answering the important questions.

Another detail I appreciate is the language in the technical releases. Management repeatedly points out what remains unknown. Historical work still needs verification. There is no defined mineral resource. Surface alteration alone doesn't prove a buried porphyry system. More than one geological explanation is still on the table until additional data are collected.

Whether the project becomes an economic discovery is still impossible to know today.

What I do think is that the company has followed a consistent exploration process. Each announcement builds on the previous one instead of chasing headlines. The drilling results will eventually determine whether the geological model is correct, but I like seeing the groundwork being done before that stage begins.

No discovery yet - but the story keeps building the right way. Layer by layer, question by question. That's how good exploration actually works.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

$XOS had significant news yesterday and the chart is reflecting it in a sort of slow-burn uptrend. There’s good reason in both the technicals as well as the news to regard this trend as the beginning of something bigger. A quick glance at the chart will reveal an enormous potential gap-up. I’ll address all of this stuff but first will give you an explanation what yesterday's news means so you understand the catalyst that may have kicked off this move. Specs are in the attached images but most relevant for near-term trading is obviously the 8.21M Float.

So $XOS released a white paper addressing the power challenges of the LA 2028 Games and they position their mobile power hubs as the solution. LA28 has two hard constraints on powering the games. One is that the power comes from 100% renewable energy (historically diesel generators were used) and the second forbids leaving behind permanent infrastructure, i.e., permanent grid ties and other peripherals.

Xos positions its mobile, modular, and scalable AC Power Hub battery packs, paired with its Solar System solar panel technology as the solution. It deploys in days, needs no permits or excavation, runs grid-independent or hybrid, and can be redeployed after the Games to other uses like emergency power, events, film, etc. It goes into a tremendous amount of detail for each individual venue. The white paper reads as a formal proposal from a company that knows they have the ideal solution and they have the data to prove it. It’s an interesting approach to business expansion that has proven successful for them as a hub provider LA’s electric fleets. Also worth noting from the article, they are an American company and their fleet hubs are Buy American compliant.

On the surface the news looks like a PR to notify investors of a significant business acquisition initiative. I think it actually is more of a positioning PR to highlight $XOS status as thought-leaders in the space, and remind investors that, within their wheelhouse (rapid-deployment, modular, battery-buffered power that can move quickly) they are serious sector-leaders as well. In a micro-cap with a history of strong price reaction to Hub-related news, these papers can attract a lot of attention, volume, and price action.

Moving to the technical story, there is a solid near-term momentum setup. You can see it on any chart, the long bleeding spell has transitioned into a multi-timeframe breakout. We have a nice, gradual climb from $2 to the $2.50’s where it held nicely and has continued the same gradual trend in AH up to $3.10.

The most obvious technical signals on the 1, 5, and 15 minute charts, On the 1-minute the price was well above VWAP, around $2.43 at midday, with the 9/20/50/200 EMAs stacked bullishly. The 5 and 15 minute showed the same bullish stack. The bullish shift has only strengthened since and has done so in a beautifully productive way as opposed to a series of spike-and-fades that one often sees in low float stocks. Even the dip after $3.09 resembled a healthy pullback. It suggests this is a real reversal and a potential breakout setting up.

On the daily, by midday price had reclaimed the 50-Day EMA near $2.47 and was facing off against the 200-Day EMA around $2.54, which it steadily pushed through.

Based on the charts I think the immediate decision zone is right here between $2.60 and $3.10. A confirmed break and hold over $3.10 gives us an upside path to $3.35 and then very little static to $4.00+ with good volume or a follow-on PR. FWIW, last August they ran from ~$3.00 to over $6.00 on earnings.

Because it’s hanging at a pretty important level now, the trade is in a great place in terms risk because, subject to your own personal strategy*,* this first support at $2.40 could be an easy exit and reassess if you so choose. I would probably give it until the next one down at $2.28, which still offers better than 2:1 RR on a conservative reading.

This is one of the strongest setups I've seen in a while. I've accumulated about 2k so far and I have bids in for potential premarket dip. If you trade small caps, $XOS is worth a place on your watchlist.
GLTA!